Luoyijun Xie

Ms. Luoyijun Xie

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
YLYingying Liao
Yingying Liao
LXLuoyijun Xie
Luoyijun Xie
JYJiahui Ye
Jiahui Ye
TCTong Chen
Tong Chen
THTong Huang
Tong Huang
Miaomiao YuanMiaomiao Yuan
Miaomiao Yuan
Schematic illustration of sprayable hydrogels for biomedical application.

30 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
LXLuoyijun Xie
Luoyijun Xie
QLQiyan Li
Qiyan Li
YLYingying Liao
Yingying Liao
ZHZihua Huang
Zihua Huang
YLYulin Liu
Yulin Liu
Miaomiao YuanMiaomiao Yuan
Miaomiao Yuan
As a promising therapy, photothermal therapy (PTT) converts near-infrared (NIR) light into heat through efficient photothermal agents (PTAs), causing a rapid increase in local temperature. Considering the importance of PTAs in the clinical application of PTT, the safety of PTAs should be carefully evaluated before their widespread use. As a promising PTA, mesoporous polydopamine (MPDA) was studied for its clinical applications for tumor photothermal therapy and drug delivery. Given the important role that intestinal microflora plays in health, the impacts of MPDA on the intestine and on intestinal microflora were systematically evaluated in this study. Through biological and animal experiments, it was found that MPDA exhibited excellent biocompatibility, in vitro and in vivo. Moreover, 16S rRNA analysis demonstrated that there was no obvious difference in the composition and classification of intestinal microflora between different drug delivery groups and the control group. The results provided new evidence that MPDA was safe to use in large doses via different drug delivery means, and this lays the foundation for further clinical applications.